Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB17170 in idiopathic pulmonary fibrosis
NCT06747923Phase 2Recruiting
- Sponsor
- SPARK Biopharma
- Start
- Jan 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SB17170 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by SPARK Biopharma. Primary endpoint: Forced Vital Capacity at 12 weeks. Started Jan 2025; status: recruiting.
02
Drugs
SB17170
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06747923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747923.